John LaMattina, Contributor

Author's details

Name: John LaMattina, Contributor
Date registered: October 19, 2016
URL: http://www.forbes.com/healthcare/

Latest posts

  1. The Demise Of A Once Promising Pancreatic Cancer Drug Is All Too Common — January 15, 2019
  2. Can The Record Breaking Number Of FDA New Drug Approvals Continue? — January 9, 2019
  3. The Claim By Bristol-Myers Squibb CEO That The New Company Will Be A ‘Magnet For Talent’ Is Naïve — January 3, 2019
  4. Lessons From The Biggest Pharma Drug Launches Of All Time — December 11, 2018
  5. Takeda Acquisition Of Shire May Bode Well For R&D Staff — December 3, 2018

Author's posts listings

The Demise Of A Once Promising Pancreatic Cancer Drug Is All Too Common

Companies as small as Nivien or as large as Pfizer find the chemical tools and run the experiments that prove or disprove medical hypotheses.

Can The Record Breaking Number Of FDA New Drug Approvals Continue?

Despite these possibilities, the boom in new drugs is likely to continue benefiting the industry and more importantly, the patients anxiously waiting for these new treatments.

The Claim By Bristol-Myers Squibb CEO That The New Company Will Be A ‘Magnet For Talent’ Is Naïve

A “magnet for talent” – really? Would you want to join an organization that is in the midst of such turmoil?

Lessons From The Biggest Pharma Drug Launches Of All Time

But given the medical breakthroughs being made, it is likely that in the coming years there will be new entries in this list – and high priced ones at that.

Takeda Acquisition Of Shire May Bode Well For R&D Staff

“We think that the fit is very strong between Takeda and Shire. We foresee minimal disruption on the R&D front.”

Novartis’ $4 Million Gene Therapy — Real Price Or A Negotiation Ploy?

We are in a wondrous age of medicine where CURES for certain types of cancer, rare diseases, blindness and other scourges are imminent. We now need to figure out how to pay for them.

No Matter What The FDA Decides, New Diabetes Drugs Will Still Require CV Outcomes Trials

CVOTs for diabetes drugs are here to stay.

In 2014 They Battled For Control. Now Pfizer’s Read And AstraZeneca’s Soriot In Different Places

Unfortunately, AstraZeneca’s revenue predictions have not lived up to Soriot’s promise.

Pharma Failures Actually Advance Medicine

The fact is we want big pharma to work on these difficult challenges. No other entity can do this.

Biopharma Attacked For Excessive Profits On Drugs For Children

These laws have transformed the way medicines are developed for pediatric populations.

Older posts «

Explore the Archive